Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review
Authors:
- Raiza QuerrerRQRaiza Querrer
- Nathália FerrareNFNathália Ferrare
- Nilce MeloNMNilce Melo
- Cristine Miron StefaniCSCristine Miron Stefani
- Paula Elaine Diniz dos ReisPRPaula Elaine Diniz dos Reis
- Carla Ruffeil Moreira MesquitaCMCarla Ruffeil Moreira Mesquita
- Gabriel Alvares BorgesGBGabriel Alvares Borges
- André Ferreira LeiteALAndré Ferreira Leite
- Paulo Tadeu FigueiredoPFPaulo Tadeu Figueiredo
- 2 November 2020
- journal article
- review article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (6) , 2811-2820
Abstract
Objective Bisphosphonates and denosumab are both antiresorptive medications, each with their own mechanism of action; yet both may result in the same adverse effect: medication-related osteonecrosis of the jaw (ONJ). The present systematic review aims to answer the following question: “Are bisphosphonate-related ONJ and denosumab-related ONJ any different, regarding clinical and imaging aspects?” Methods This review followed the Joanna Briggs Review’s Manual, and the searches were performed on PubMed, Cochrane, Scopus, Web of Science, and Lilacs databases and on the grey literature (ProQuest, Open Grey, and Google Scholar). Results The searches resulted in 7535 articles that were critically assessed. Based on the selection criteria, seven studies were included in the review: five cross-sectional studies and two randomized clinical trials. A total of 7755 patients composed the final population. An increase in bone sequestra, cortical bone lysis, and bone density was observed in bisphosphonate-related ONJ, while larger bone sequestra, more frequent periosteal reactions, and mandibular canal enhancement were noted in denosumab-related ONJ. Conclusion This systematic review demonstrated that the imaging characteristics of bisphosphonate-related and denosumab-related ONJ are not similar. Although clinically similar conditions, they were found to be radiographically distinct. More studies are necessary to further elucidate these differences.Keywords
This publication has 28 references indexed in Scilit:
- Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastasesAnnals of Oncology, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- The role and efficacy of denosumab in the treatment of osteoporosis: an updateExpert Opinion on Drug Safety, 2010
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJournal of Clinical Oncology, 2010
- Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jawsOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Imaging Findings in Bisphosphonate-Related Osteonecrosis of JawsJournal of Oral and Maxillofacial Surgery, 2009
- Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone DiseasesJournal of Clinical Densitometry, 2008
- Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancerOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2007
- Clodronate and Liposome-Encapsulated Clodronate Are Metabolized to a Toxic ATP Analog, Adenosine 5′-(β,γ-Dichloromethylene) Triphosphate, by Mammalian Cells In VitroJournal of Bone and Mineral Research, 1997